Philips Q3 2026 net income falls to €28M

The EUR 288 million Respironics provision affected reported results, while Philips reiterated its 2026 sales, margin and free cash flow outlook ranges.

Available on EDGAR 11/03/2026 - 08:11 AM EST Accepted by SEC EDGAR 11/03/2026 - 08:11 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Koninklijke Philips N.V. (PHG) reported Q3 2026 sales of EUR 4.393 billion, versus EUR 4.302 billion a year earlier, with 3% comparable sales growth and 8% comparable order intake growth. Adjusted EBITA was EUR 569 million, up from EUR 531 million, and its margin rose to 13.0% from 12.3%. Operating cash flow was EUR 544 million and free cash flow EUR 384 million.

Net income fell to EUR 28 million from EUR 187 million. Philips recorded a EUR 288 million provision after Philips Respironics reached an agreement in principle with the U.S. Department of Justice to resolve previously disclosed criminal and civil investigations related to the recall. The settlement is subject to finalization of relevant documentation; payment is expected in the first quarter of 2027, and the outlook assumes that payment.

Philips reiterated its 2026 outlook: comparable sales growth of 3%-4.5%, adjusted EBITA margin of 13.5%-14.0% including a U.S. tariff refund benefit of approximately 1%, and free cash flow of EUR 1.5-1.7 billion including a net U.S. tariff refund benefit of approximately EUR 200 million. The outlook excludes other ongoing Philips Respironics-related proceedings.

3 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

How the balance works

Positive

• Moderate pointAdjusted EBITA rose to EUR 569 million from EUR 531 million.
• Moderate pointOperating cash flow was EUR 544 million, versus EUR 327 million.
• Moderate pointFree cash flow was EUR 384 million, versus EUR 172 million.

Negative

• Moderate pointNet income fell to EUR 28 million from EUR 187 million.

Filing Explained

The Amsterdam Enterprise Chamber denied certain investors’ requests for an investigation into Philips’ Respironics-related affairs.

Philips reports that it issued EUR 650 million of fixed-rate notes due 2034 in the third quarter, adding debt to its financing structure.

The company says an amount equivalent to the notes’ gross proceeds will finance taxonomy-aligned economic activities, and identifies the notes as an EU Green Bond under the new European Green Bond Standard.

Key Figures

Sales: EUR 4.393 billion Comparable order intake growth: 8% Adjusted EBITA: EUR 569 million +5 more

8 metrics

Sales EUR 4.393 billion Q3 2026; EUR 4.302 billion in Q3 2025

Comparable order intake growth 8% Q3 2026

Adjusted EBITA EUR 569 million Q3 2026; EUR 531 million in Q3 2025

Adjusted EBITA margin 13.0% Q3 2026; 12.3% in Q3 2025

Net income EUR 28 million Q3 2026; EUR 187 million in Q3 2025

Operating cash flow EUR 544 million Q3 2026; EUR 327 million in Q3 2025

Free cash flow EUR 384 million Q3 2026; EUR 172 million in Q3 2025

Respironics DOJ settlement provision EUR 288 million Recorded in Q3 2026

Key Terms

Comparable order intake, Adjusted EBITA, Free cash flow, European Green Bond Standard

4 terms

Comparable order intake financial

"Comparable order intake increased by 8%"

Adjusted EBITA financial

"Adjusted EBITA margin increased 70 basis points to 13.0%"

Adjusted EBITA is a measure of a company’s operating profit before interest, taxes and amortization, further modified to remove one-time or unusual items so it reflects ongoing business earnings. It matters to investors because it aims to show the company’s core cash-making ability — like listening to an engine without road noise — making comparisons across periods or peers easier, though companies may differ in what they exclude.

Free cash flow financial

"Free cash flow increased to EUR 384 million"

Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.

European Green Bond Standard regulatory

"under the new European Green Bond Standard"

A regulatory standard created by the European Union that sets rules for issuing a labelled “European green bond.” It requires that the bond’s proceeds finance activities aligned with the EU Taxonomy for environmentally sustainable economic activities, that issuers disclose how proceeds are used and report environmental impact, and that alignment is checked by an independent verifier; participation is voluntary but gives a harmonized label and mandatory minimum safeguards under the EU framework.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were PHG's Q3 2026 results?

PHG reported sales of EUR 4.393 billion and 3% comparable sales growth in Q3 2026. Comparable order intake grew 8%, while adjusted EBITA was EUR 569 million, versus EUR 531 million in Q3 2025.

What is PHG's 2026 outlook?

Philips reiterated comparable sales growth of 3%-4.5%, an adjusted EBITA margin of 13.5%-14.0% including a U.S. tariff refund benefit of approximately 1%, and free cash flow of EUR 1.5-1.7 billion including a net U.S. tariff refund benefit of approximately EUR 200 million. The outlook assumes payment of the DOJ settlement in the first quarter of 2027.

What is the status of the Philips Respironics DOJ settlement?

Philips Respironics reached an agreement in principle with the U.S. Department of Justice to resolve previously disclosed criminal and civil investigations related to the recall. Philips recorded a EUR 288 million provision; the settlement is subject to finalization of relevant documentation, with payment expected in the first quarter of 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________________________________________________________

FORM 6-K

____________________________________________________________________________

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

November 3, 2026

____________________________________________________________________________

KONINKLIJKE PHILIPS N.V.

(Exact name of registrant as specified in its charter)

____________________________________________________________________________

Royal Philips

(Translation of registrant’s name into English)

The Netherlands

(Jurisdiction of incorporation or organization)

Prinses Irenestraat 59, 1077 WV Amsterdam, The Netherlands

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐        No ☒

Name and address of person authorized to receive notices and communications from the Securities and Exchange Commission:

M.J. van Ginneken
Koninklijke Philips N.V.
Prinses Irenestraat 59
1077 WV Amsterdam – The Netherlands

This report comprises a copy of the following report:

“Philips' Third Quarter Results 2026”, dated November 3, 2026.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf, by the undersigned, thereunto duly authorized at Amsterdam, on the 3rd day of November, 2026.

KONINKLIJKE PHILIPS N.V.

/s/ M.J. van Ginneken
(Chief Legal Officer)

			Quarterly report
			Q3 2026

Philips delivers strong order intake growth, comparable sales growth and strong margin expansion in Q3; 2026 outlook reiterated

Amsterdam, November 3, 2026

Q3 2026 Group performance

•Comparable order intake increased by 8%, driven by strong Diagnosis & Treatment

•Group sales of EUR 4.4 billion, reflecting 3% comparable sales growth

•Income from operations of EUR 165 million

•Adjusted EBITA margin increased 70 basis points to 13.0%, with expansion across all business segments

•Operating cash flow of EUR 544 million; free cash flow of EUR 384 million

•Respironics reached agreement in principle with the US Department of Justice

•Philips reiterates its full-year 2026 outlook

Roy Jakobs, CEO of Royal Philips:

“We delivered an excellent 8% comparable order intake, led by broad-based order momentum in Diagnosis & Treatment, and 3% comparable sales growth in the third quarter, led by Personal Health and Connected Care. Our innovations and productivity measures drove continued margin expansion across all business segments.

We are executing our plan to accelerate profitable growth, with strong customer demand for our latest AI-enabled innovations, including our new CT platforms Verida and Rembra, our latest ultrasound system Alturion, and our HealthSuite Imaging cloud solution. These innovations demonstrate how our platforms bring together hardware, software, data and AI to create greater value for customers. We look forward to showcasing our next innovations at RSNA later this month.

We continue to make progress in resolving the consequences of the Sleep & Respiratory Care recall. The Respironics agreement in principle with the US Department of Justice marks an important step in this process.

Our year-to-date results, together with our strong order book, give us confidence in delivering our full-year outlook and achieving our medium-term ambitions. As we move forward in collaboration with customers, our hardworking teams around the world are focused on putting quality at the heart of our operations as we deliver better care for more people.”

Group and segment performance

Comparable order intake grew 8%, driven by strong growth in Diagnosis & Treatment. Comparable sales increased by 3%, driven by Personal Health and Connected Care.

Adjusted EBITA margin increased 70 basis points to 13.0%, mainly driven by higher sales, higher gross margin and productivity measures, partly offset by cost inflation. Net cash flows from operating activities increased to EUR 544 million, mainly driven by higher cash earnings and lower working capital outflows. Free cash flow increased to EUR 384 million.

Diagnosis & Treatment comparable sales growth was flat. Growth in Image Guided Therapy was offset by a decline in Precision Diagnosis, mainly due to phasing of Ultrasound sales and lower sales in China as previously communicated at Q2. Adjusted EBITA margin increased 50 basis points to 12.3%, mainly driven by gross margin from innovation and productivity measures, partly offset by cost inflation.

Connected Care comparable sales increased by 5%, driven by growth in all businesses. Adjusted EBITA margin increased 190 basis points to 13.3%, mainly driven by higher sales, higher gross margin, and productivity measures, partly offset by cost inflation.

Personal Health comparable sales increased by 8%. Adjusted EBITA margin increased 60 basis points to 17.7%, mainly driven by higher sales and productivity measures, partly offset by advertising and promotion spend.

Quarterly Report 2026 - Q3 3

Innovation highlights

•Philips is accelerating innovation in image-guided therapy. In the Netherlands, Philips is investing EUR 50 million in AI, robotics and advanced imaging, alongside over EUR 100 million from the Dutch government and a further EUR 150 million in private financing by Invest-NL and institutional investors, including pension funds. In the US, an ARPA-H award of up to USD 34 million will support AI-enabled robotic stroke care on the Azurion platform.

•The Philips-coordinated European COMBINE-CT project advanced into clinical validation, launching five clinical studies to evaluate an integrated care pathway enabled by AI-powered CT and Spectral CT imaging solutions.

•Philips extended its monitoring partnership with one of the largest US health systems through 2034. The national agreement covers equipment and services, expands the use of Philips’ Capsule platform, and supports future technology needs.

•Ontario Health in Canada selected the Philips Enterprise Imaging Vendor Neutral Archive to modernize province-wide imaging infrastructure and connect patient information across care settings. This Vendor Neutral Archive will support the sharing of more than 20 million imaging studies annually across more than 150 hospitals and 50 imaging clinics, helping enable a holistic patient view and more timely access to care.

•Philips is supporting major healthcare programs in Latin America, including the modernization of 50 public hospitals in Venezuela, and an expanded partnership with Mexico’s largest public healthcare institution, IMSS. The projects bring advanced imaging, image-guided therapy and monitoring technologies to more patients, expanding access to diagnostic, cardiac, neurological and stroke care.

•Philips signed a long-term strategic partnership with Asia Medical Group to advance integrated cardiovascular care in China. The partnership will focus on clinical care, training, research and international collaboration, combining Philips’ diagnostic imaging and image-guided therapy capabilities with Asia Medical Group’s cardiovascular expertise.

•Personal Health launched innovations across oral care, beauty and mother and child care. These include the AI-powered Sonicare DiamondClean 9900 Prestige, the first at-home IPL with real-time guidance Lumea 9900 Pro, and Philips Avent’s first fully wearable Natural Care breast pump, bringing more personalized and premium solutions to consumers.

Productivity

Disciplined cost management and productivity initiatives delivered EUR 170 million in net savings in the quarter and EUR 427 million year-to-date. The company remains on track to deliver EUR 1.5 billion in savings under its 2026-2028 productivity program.

Progress on Respironics-related legal proceedings

Philips Respironics reached an agreement in principle with the US Department of Justice (DOJ) to resolve the previously disclosed criminal and civil investigations related to the Respironics recall. As a result, Philips recorded a provision of EUR 288 million in the third quarter of 2026. The settlement is subject to finalization of the relevant documentation; payment is expected in the first quarter of 2027.

Also in the third quarter, the Enterprise Chamber of the Amsterdam Court of Appeal denied requests from certain investors for an investigation into the affairs of Philips in connection with the Respironics recall.

Outlook

Philips reiterates its full-year 2026 outlook:

•Comparable sales growth: 3%-4.5%

•Adjusted EBITA margin: 13.5%-14.0%, including a US tariff refund benefit of approximately 1%

•Free cash flow: EUR 1.5-1.7 billion, including a net US tariff refund benefit of approximately EUR 200 million

Within the context of an uncertain macro-environment, Philips' 2026 outlook includes currently known tariffs and assumes payment of the US Department of Justice settlement in the first quarter of 2027. The outlook excludes other ongoing Philips Respironics-related proceedings, including the investigation by the US State Attorneys General.

Capital allocation

In the third quarter, Philips issued EUR 650 million fixed rate notes due 2034 (the “Notes”) under its European Medium Term Note program. The Notes are the healthcare industry's first EU Green Bond under the new European Green Bond Standard and were 2.7 times oversubscribed, reflecting strong investor demand. An amount equivalent to the gross proceeds will be used to finance taxonomy-aligned economic activities as referred to in the Philips European Green Bond Factsheet, supporting Philips in delivering on its 2030 Impact Ambitions. See here for more information on Philips' current debt structure.

Further information: conference call, video webcast and website

Roy Jakobs, CEO, and Charlotte Hanneman, CFO, will host a conference call for investors and analysts at 10:00 am CET on November 3, 2026, to discuss the results. A live webcast will be available on the Philips Investor Relations webpage and can be accessed here. A replay and related materials, including additional information on the outlook and forward-looking statements, will be available on the Philips Investor Relations webpage.

Quarterly Report 2026 - Q3 4

Third quarter highlights

Key data in millions of EUR unless otherwise stated*

			Q3 2026			Q3 2025
Sales			4,393			4,302
Nominal sales growth			2		%	(2		%)
Comparable sales growth ¹			3		%	3		%
Comparable order intake ²			8		%	8		%
Income from operations			165			330
as a % of sales			4		%	8		%
Financial income (expenses), net			(42)			(57)
Results of associates			(1)			2
Income tax (expense) benefit			(92)			(87)
Income from continuing operations			30			188
Discontinued operations, net of income taxes			(2)			(1)
Net income			28			187
Earnings per common share (EPS)
Income from continuing operations attributable to shareholders ³ (in EUR) - diluted			0.03			0.19
Adjusted income from continuing operations attributable to shareholders ³ (in EUR) - diluted ¹			0.40			0.36
Net income attributable to shareholders ³ (in EUR) - diluted			0.03			0.19
EBITA ¹			216			409
as a % of sales			4.9		%	9.5		%
Adjusted EBITA ¹			569			531
as a % of sales			13.0		%	12.3		%
Adjusted EBITDA ¹			772			738
as a % of sales			17.6		%	17.2		%

1Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information

2Comparable order intake is presented when discussing the Philips Group's performance. For the definition of this measure, refer to chapter Further information, section Other Key Performance Indicators, of the Annual Report 2025.

3Shareholders refers to shareholders of Koninklijke Philips N.V.

•Comparable sales increased by 3%, mainly driven by mid-single-digit growth in Connected Care and high-single-digit growth in Personal Health. In Diagnosis & Treatment, comparable sales growth was flat.

•Income from operations decreased by EUR 165 million, mainly due to a EUR 288 million Respironics DOJ settlement provision, partly offset by higher sales and lower cost of sales.

•Adjusted EBITA increased to EUR 569 million and the margin improved to 13.0%, mainly driven by higher sales, higher gross margin, and productivity measures, partly offset by cost inflation.

•Restructuring, acquisition-related and other items amounted to charges of EUR 353 million, compared with EUR 122 million in Q3 2025. Q3 2026 mainly includes a EUR 288 million Respironics DOJ settlement provision, EUR 34 million of other Respironics-related charges, and EUR 18 million restructuring and acquisition-related charges.

•Income tax expense increased by EUR 5 million, mainly due to the tax treatment of the Respironics DOJ settlement provision in Q3 2026.

•Net income decreased to EUR 28 million, mainly due to income from operations as explained above, partly offset by lower net financial expenses.

Sales per geographic area in millions of EUR unless otherwise stated

									% change
			Q3 2026			Q3 2025			nominal			comparable ¹
Western Europe			971			933			4		%	5		%
North America			1,864			1,833			2		%	1		%
Other mature geographies			317			320			(1		%)	3		%
Mature geographies			3,152			3,086			2		%	3		%
Growth geographies			1,240			1,217			2		%	3		%
Philips Group			4,393			4,302			2		%	3		%

1Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information

•Comparable sales in Mature geographies showed 3% growth, mainly driven by Western Europe.

•Growth geographies showed 3% comparable sales growth, mainly driven by Central Eastern Europe, the Indian subcontinent and certain markets in the Southeast Asia and Pacific region.

Cash and cash equivalents balance in millions of EUR

			Q3 2026			Q3 2025
Beginning cash balance			1,789			1,822
Free cash flow ¹			384			172
Net cash flows from operating activities			544			327
Net capital expenditures			(160)			(155)
Other cash flows from investing activities			9			(4)
Treasury shares transactions			-			7
Changes in debt			603			(42)
Dividend paid to shareholders			(37)			(33)
Other cash flow items			2			(11)
Ending cash balance			2,751			1,912

1Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information

•Net cash flows from operating activities increased, mainly driven by higher cash earnings and lower working capital outflows.

•Changes in debt in Q3 2026 includes the new EUR green bonds issuance amounting to EUR 646 million, partly offset by debt repayments.

•Dividend paid to shareholders reflects the payment of the dividend-related withholding tax.

•Other cash flow items mainly reflects the foreign currency impact on the cash balance.

Amounts may not add up due to rounding.*

Quarterly Report 2026 - Q3 5

Performance per segment

Diagnosis & Treatment

Key data in millions of EUR unless otherwise stated*

			Q3 2026			Q3 2025
Sales			2,085			2,080
Nominal sales growth			0		%	(3		%)
Comparable sales growth ¹			0		%	1		%
Income from operations			219			200
as a % of sales			10.5		%	9.6		%
EBITA ¹			239			217
as a % of sales			11.5		%	10.5		%
Adjusted EBITA ¹			255			246
as a % of sales			12.3		%	11.8		%
Adjusted EBITDA ¹			301			291
as a % of sales			14.5		%	14.0		%

1Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information

•Comparable sales growth was flat. Mid-single-digit growth in Image Guided Therapy was offset by a mid-single-digit decline in Precision Diagnosis, mainly due to phasing of Ultrasound sales and lower sales in China.

•Mature geographies showed low-single-digit growth. This was offset by a mid-single-digit decline in Growth geographies.

•Adjusted EBITA increased to EUR 255 million and the margin improved by 50 basis points to 12.3%, mainly driven by gross margin from innovation and productivity measures, partly offset by cost inflation.

•Restructuring, acquisition-related and other items amounted to EUR 17 million, compared with EUR 29 million in Q3 2025.

Connected Care

Key data in millions of EUR unless otherwise stated

			Q3 2026			Q3 2025
Sales			1,176			1,200
Nominal sales growth			(2		%)	(1		%)
Comparable sales growth ¹			5		%	5		%
Income from operations			(195)			12
as a % of sales			(16.6		%)	1.0		%
EBITA ¹			(170)			67
as a % of sales			(14.5		%)	5.6		%
Adjusted EBITA ¹			157			137
as a % of sales			13.3		%	11.4		%
Adjusted EBITDA ¹			212			201
as a % of sales			18.0		%	16.7		%

1Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information

•Comparable sales increased by 5%, driven by growth in all Businesses.

•Comparable sales in Mature geographies showed mid-single-digit growth, and Growth geographies recorded double-digit growth.

•Adjusted EBITA increased to EUR 157 million and the margin improved by 190 basis points to 13.3%, mainly driven by higher sales, gross margin, favorable mix effects, and productivity measures, partly offset by cost inflation.

•Restructuring, acquisition-related and other items amounted to EUR 327 million, compared with charges of EUR 70 million in Q3 2025. Q3 2026 mainly includes a EUR 288 million Respironics DOJ settlement provision, and EUR 34 million of other Respironics-related charges.

Personal Health

Key data in millions of EUR unless otherwise stated

			Q3 2026			Q3 2025
Sales			953			883
Nominal sales growth			8		%	6		%
Comparable sales growth ¹			8		%	11		%
Income from operations			165			143
as a % of sales			17.3		%	16.2		%
EBITA ¹			169			147
as a % of sales			17.7		%	16.6		%
Adjusted EBITA ¹			168			151
as a % of sales			17.7		%	17.1		%
Adjusted EBITDA ¹			195			172
as a % of sales			20.4		%	19.4		%

1Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information

•Comparable sales increased by 8%, driven by double-digit growth in Growth geographies and mid-single-digit growth in Mature geographies.

•Adjusted EBITA increased to EUR 168 million and the margin improved by 60 basis points to 17.7%, mainly driven by higher sales and productivity measures, partly offset by advertising and promotion spend.

•Restructuring, acquisition-related and other items amounted to nil in Q3 2026, compared with charges of EUR 4 million in Q3 2025.

Other

Key data in millions of EUR unless otherwise stated

			Q3 2026			Q3 2025
Sales			179			140
Income from operations			(24)			(25)
EBITA ¹			(21)			(22)
Adjusted EBITA ¹ of:			(12)			(3)
IP Royalties			74			73
Innovation			(18)			(11)
Central costs			(67)			(54)
Other			-			(12)
Adjusted EBITDA ¹			64			74

1Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information

•Segment Other sales increased by EUR 39 million, mainly reflecting activities related to a divestment, which is excluded from comparable sales growth.

•Adjusted EBITA decreased by EUR 9 million, mainly due to phasing in central costs.

•Restructuring, acquisition-related and other items amounted to charges of EUR 9 million, compared with EUR 19 million in Q3 2025.

Amounts may not add up due to rounding.*

Quarterly Report 2026 - Q3 6

Forward-looking statements
and other information

Forward-looking statements

This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future Adjusted EBITA*, future restructuring and acquisition-related charges and other costs, future developments in Philips’ organic business and the completion of acquisitions and divestments. Forward-looking statements can be identified generally as those containing words such as “anticipates”, “assumes”, “believes”, “estimates”, “expects”, “should”, “will”, “will likely result”, “forecast”, “outlook”, “projects”, “may” or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

These factors include, but are not limited to, macro-economic and geopolitical changes – including the war in Ukraine and ongoing tensions in the Middle East – as well as measures such as enacted and proposed tariffs and trade actions introduced in response to rising global tensions; Philips’ ability to keep pace with the changing health technology environment; Philips’ ability to gain leadership in artificial intelligence and health informatics in response to developments in the health technology industry; integration of acquisitions and their delivery on business plans and value creation expectations; ability to meet expectations with respect to ESG-related matters; securing and maintaining Philips’ intellectual property rights, and unauthorized use of third-party intellectual property rights; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations; the resilience of our supply chain; challenges in simplifying our organization and our ways of working; attracting and retaining personnel; breach of cybersecurity; challenges in driving operational excellence and speed in bringing innovations to market; treasury and financing risks; tax risks; reliability of internal controls; compliance with regulations and standards involving quality, product safety, (cyber) security and artificial intelligence; and compliance with business conduct rules and regulations including privacy, existing and upcoming ESG disclosure and due diligence requirements. As a result, Philips’ actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Further information chapter included in the Annual Report 2025.

Third-party market share data

Statements regarding market share contained in this document, including those regarding Philips’ competitive position, are based on outside sources such as specialized research institutes, as well as industry and dealer panels, in combination with management estimates. Where information is not yet available to Philips, market share statements may also be based on estimates and projections prepared by management and/or based on outside sources of information. Management’s estimates of rankings are based on order intake or sales, depending on the business.

Market Abuse Regulation

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Use of non-IFRS information

In presenting and discussing the Philips Group’s financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2025.

Presentation

All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2025. Certain prior-year balances have been reclassified to conform to the current period presentation.

* Non-IFRS financial measure. Refer to the Reconciliation of non-IFRS information

Quarterly Report 2026 - Q3 7

Condensed consolidated statements of income

In millions of EUR unless otherwise stated*

			Q3						January to September
			2026			2025			2026			2025
Sales			4,393			4,302			12,658			12,736
Cost of sales			(2,353)			(2,392)			(6,702)			(6,966)
Gross margin			2,040			1,911			5,956			5,770
Selling expenses			(1,016)			(1,024)			(3,077)			(3,195)
General and administrative expenses			(158)			(154)			(490)			(470)
Research and development expenses			(410)			(414)			(1,288)			(1,273)
Other business income			2			21			233			75
Other business expenses			(293)			(10)			(318)			(23)
Income from operations			165			330			1,015			884
Financial income			42			21			106			75
Financial expenses			(84)			(78)			(257)			(238)
Results of associates			(1)			2			(6)			(6)
Income before taxes			122			275			858			716
Income tax (expense) benefit			(92)			(87)			(296)			(208)
Income from continuing operations			30			188			562			508
Discontinued operations, net of income taxes			(2)			(1)			(2)			(8)
Net income			28			187			560			499
Attribution of net income
Net income attributable to shareholders ¹			27			184			562			500
Net income attributable to non-controlling interests			1			3			(2)			(1)

1Shareholders refers to shareholders of Koninklijke Philips N.V.

Philips Group Earnings per common share attributable to shareholders of Koninklijke Philips N.V.

			Q3						January to September
			2026			2025			2026			2025
Weighted average number of common shares outstanding (after deduction of treasury shares) during the period (in thousands):
Basic			977,553			950,790			961,566			947,264
Diluted			989,899			963,844			976,687			960,389
Basic earnings per common share attributable to shareholders of Koninklijke Philips N.V (in EUR)
Income from continuing operations			0.03			0.19			0.59			0.54
Income from discontinued operations			-			-			-			(0.01)
Net income			0.03			0.19			0.58			0.53
Diluted earnings per common share attributable to shareholders of Koninklijke Philips N.V. (in EUR)
Income from continuing operations			0.03			0.19			0.58			0.53
Income from discontinued operations			-			-			-			(0.01)
Net income			0.03			0.19			0.58			0.52

Amounts may not add up due to rounding.*

Quarterly Report 2026 - Q3 8

Condensed consolidated statements of comprehensive income

in millions of EUR*

			Q3						January to September
			2026			2025			2026			2025
Net income for the period			28			187			560			499
Pensions and other post-employment plans:
Remeasurement, before tax			-			-			1			1
Income tax effect on remeasurements			1			(1)			4			2
Financial assets fair value through OCI:
Net current-period change, before tax			(7)			(3)			(19)			(28)
Income tax effect on net current-period change			3			-			4			4
Total of items that will not be reclassified to Income statement			(3)			(3)			(11)			(21)
Currency translation differences:
Net current-period change, before tax			94			(41)			468			(1,627)
Reclassification adjustment for (gain) loss realized			-			(13)			8			(13)
Income tax effect on net current-period change and reclassification			-			2			(1)			3
Cash flow hedges:
Net current-period change, before tax			(23)			8			(17)			45
Reclassification adjustment for (gain) loss realized			(11)			(3)			(45)			(5)
Income tax effect on net current-period change and reclassification			8			(1)			15			(11)
Total of items that are or may be reclassified to Income statement			67			(48)			429			(1,607)
Other comprehensive income for the period			64			(51)			419			(1,629)
Total comprehensive income for the period			91			136			979			(1,130)
Total comprehensive income attributable to:
Shareholders of Koninklijke Philips N.V.			91			133			981			(1,125)
Non-controlling interests			1			2			(2)			(4)

Amounts may not add up due to rounding.*

Quarterly Report 2026 - Q3 9

Condensed consolidated balance sheets

in millions of EUR*

			September 30, 2026			December 31, 2025
Non-current assets:
Property, plant and equipment			2,204			2,217
Goodwill			9,741			9,271
Intangible assets excluding goodwill			2,538			2,569
Non-current receivables			211			210
Investments in associates			153			148
Other non-current financial assets			723			704
Deferred tax assets			1,829			1,773
Other non-current assets			120			119
Total non-current assets			17,520			17,012
Current assets:
Inventories			3,404			2,870
Other current assets			687			529
Current derivative financial assets			50			81
Income tax receivable			49			60
Current receivables			3,567			3,530
Assets classified as held for sale			-			67
Cash and cash equivalents			2,751			2,794
Total current assets			10,507			9,932
Total assets			28,027			26,944
Equity:
Shareholders’ equity			11,580			10,957
Non-controlling interests			29			32
Group equity			11,609			10,990
Non-current liabilities:
Long-term debt			6,985			6,934
Long-term provisions			877			915
Deferred tax liabilities			74			93
Non-current contract liabilities			490			458
Other non-current liabilities			84			47
Total non-current liabilities			8,509			8,446
Current liabilities:
Short-term debt			1,154			1,151
Current derivative financial liabilities			64			34
Income tax liabilities			258			174
Accounts payable			2,136			1,927
Accrued liabilities			1,495			1,616
Current contract liabilities			1,635			1,490
Short-term provisions			815			712
Liabilities directly associated with assets held for sale			-			9
Other current liabilities			351			395
Total current liabilities			7,909			7,509
Total liabilities			16,418			15,954
Total liabilities and group equity			28,027			26,944

Amounts may not add up due to rounding.*

Quarterly Report 2026 - Q3 10

Condensed consolidated statements of cash flows

in millions of EUR*

			Q3						January to September
			2026			2025			2026			2025
Cash flows from operating activities:
Net income (loss)			28			187			560			499
Results of discontinued operations - net of income tax			2			1			2			8
Adjustments to reconcile net income to net cash provided by (used for) operating activities:
Depreciation, amortization and impairment of assets			254			303			901			846
Share-based compensation			43			32			124			111
Net loss (gain) on sale of assets			1			(1)			(80)			(2)
Interest income			(24)			(17)			(73)			(61)
Interest expense on debt, borrowings and other liabilities			77			68			225			200
Results of associates			1			(1)			-			7
Income tax expense			92			87			296			208
Decrease (increase) in working capital:			(66)			(206)			(460)			(542)
Decrease (increase) in receivables and other current assets			(13)			(24)			(89)			190
Decrease (increase) in inventories			(201)			(102)			(540)			(470)
Increase (decrease) in accounts payable, accrued and other current liabilities			148			(80)			168			(263)
Decrease (increase) in non-current receivables and other assets			3			20			(3)			(68)
Increase (decrease) in other liabilities			22			12			59			4
Increase (decrease) in provisions			261			(66)			31			(1,206)
Other items			(42)			(5)			(107)			80
Interest received			21			17			71			60
Interest paid			(75)			(63)			(248)			(213)
Dividends received from investments in associates			2			2			8			13
Income taxes received/ (paid)			(56)			(43)			(197)			(164)
Net cash provided by (used for) operating activities			544			327			1,108			(219)
Cash flows from investing activities:
Net capital expenditures			(160)			(155)			(473)			(469)
Purchase of intangible assets			(26)			(23)			(80)			(92)
Expenditures on development assets			(61)			(67)			(189)			(198)
Capital expenditures on property, plant and equipment			(75)			(68)			(212)			(186)
Proceeds from sales of property, plant and equipment			2			3			9			7
Net proceeds from (cash used for) derivatives and current financial assets			12			-			9			(71)
Purchase of other non-current financial assets			(3)			(9)			(41)			(35)
Proceeds from other non-current financial assets			7			3			36			42
Purchase of businesses, net of cash acquired			(4)			3			(236)			2
Sale of interests in businesses, net of cash disposed of			(2)			-			130			(9)
Net cash provided by (used for) investing activities			(150)			(158)			(576)			(541)
Cash flows from financing activities:
Proceeds from issuance of (payments on) short-term debt			(1)			(9)			(42)			6
Principal payments on short-term portion of long-term debt			(57)			(55)			(910)			(296)
Proceeds from issuance of long-term debt			661			22			754			1,041
Re-issuance of treasury shares			1			7			15			8
Purchase of treasury shares			-			-			(69)			-
Dividends paid to shareholders of Koninklijke Philips N.V.			(37)			(33)			(358)			(328)
Dividends paid to shareholders of non-controlling interests			(1)			-			(2)			(2)
Net cash provided by (used for) financing activities			566			(68)			(610)			429
Net cash provided by (used for) continuing operations			960			100			(79)			(330)
Net cash provided by (used for) discontinued operations			-			-			-			(10)
Net cash provided by (used for) continuing and discontinued operations			960			100			(79)			(340)
Effect of change in exchange rates on cash and cash equivalents			3			(11)			36			(149)
Cash and cash equivalents at the beginning of the period			1,789			1,822			2,794			2,401
Cash and cash equivalents at the end of the period			2,751			1,912			2,751			1,912

Amounts may not add up due to rounding.*

Quarterly Report 2026 - Q3 11

Condensed consolidated statements of changes in equity

in millions of EUR*

			Common shares			Capital in excess of par value						Cash flow hedges			Currency translation differences			Treasury shares			Share-based compensation			Fair value through OCI			Retained earnings						Total shareholders’ equity			Non-controlling interests			Group equity
												Reserves
Balance as of December 31, 2024			188			6,755						1			2,014			(411)			(102)			(90)			3,650						12,006			37			12,043
Net income			-			-						-			-			-			-			-			500						500			(1)			499
Other comprehensive income (loss)			-			-						29			(1,632)			-			-			(25)			3						(1,625)			(4)			(1,629)
Total comprehensive income (loss)			-			-						29			(1,632)			-			-			(25)			503						(1,125)			(4)			(1,130)
Dividend distributed			5			457						-			-			-			-			-			(789)						(328)			(2)			(330)
Transfer on disposal of equity investments at FVTOCI			-			-						-			-			-			-			(2)			2						-			-			-
Forward contracts			-			-						-			-			-			-			-			(125)						(125)			-			(125)
Share-based compensation plans			-			-						-			-			99			57			-			(33)						124			-			124
Balance as of September 30, 2025			193			7,212						30			382			(312)			(45)			(116)			3,208						10,552			31			10,583
Balance as of December 31, 2025			193			7,212						33			347			(298)			(17)			(89)			3,575						10,957			32			10,990
Net income			-			-						-			-			-			-			-			562						562			(2)			560
Other comprehensive income (loss)			-			-						(46)			475			-			-			(16)			5						419			-			419
Total comprehensive income (loss)			-			-						(46)			475			-			-			(16)			567						981			(2)			979
Dividend distributed			4			453						-			-			-			-			-			(815)						(358)			(2)			(359)
Transfer on disposal of equity investments at FVTOCI			-			-						-			-			-			-			2			(2)						-			-			-
Forward contracts			-			-						-			-			-			-			-			(73)						(73)			-			(73)
Share-based compensation plans			-			-						-			-			188			(74)			-			(41)						73			-			73
Balance as of September 30, 2026			197			7,665						(13)			823			(110)			(91)			(103)			3,212						11,580			29			11,609

Amounts may not add up due to rounding.*

Quarterly Report 2026 - Q3 12

Reconciliation of non-IFRS information

Certain non-IFRS financial measures are presented when discussing the Philips Group’s performance:

•Comparable sales growth

•Adjusted income from continuing operations attributable to shareholders

•Adjusted income from continuing operations attributable to shareholders per common share (in EUR) - diluted (Adjusted EPS)

•EBITA

•Adjusted EBITA

•Adjusted EBITDA

•Free cash flow

•Net debt : group equity ratio

For the definitions of the non-IFRS financial measures listed above, refer to chapter Further information, section Reconciliation of non-IFRS information, of the Annual Report 2025 and to the Forward-looking statements and other information.

Comparable order intake is not a financial measure, but is presented when discussing the Philips Group’s performance. Refer to Forward-looking statements and other information.

Sales growth composition in %

			Q3 2026												January to September
			nominal growth			consolidation changes			currency effects			comparable growth			nominal growth			consolidation changes			currency effects			comparable growth
2026 versus 2025
Diagnosis & Treatment			0.2		%	(0.1		%)	(0.5		%)	(0.3		%)	(1.8		%)	0.0		%	3.1		%	1.3		%
Connected Care			(2.0		%)	7.0		%	(0.1		%)	5.0		%	(6.4		%)	5.6		%	4.2		%	3.4		%
Personal Health			7.9		%	0.0		%	(0.2		%)	7.7		%	4.9		%	0.0		%	3.4		%	8.3		%
Philips Group			2.1		%	1.0		%	(0.3		%)	2.7		%	(0.6		%)	0.7		%	3.4		%	3.5		%

Adjusted income from continuing operations attributable to shareholders 1 in millions of EUR unless otherwise stated

			Q3						January to September
			2026			2025			2026			2025
Net income			28			187			560			499
Discontinued operations, net of income taxes			2			1			2			8
Income from continuing operations			30			188			562			508
Income from continuing operations attributable to non-controlling interests			(1)			(3)			2			1
Income from continuing operations attributable to shareholders ¹			29			185			565			508
Adjustments for:
Amortization and impairment of acquired intangible assets			52			79			189			189
Restructuring and acquisition-related charges			18			57			(45)			169
Other items:			335			65			479			182
Respironics DOJ settlement provision			288			-			288			-
Respironics consent decree charges			31			20			80			68
Portfolio realignment charges			-			-			50			-
Respironics field-action running costs			3			20			39			91
Quality actions			6			23			16			42
Contract settlement gain			-			-			-			(23)
Remaining items			7			2			7			4
Net finance expenses			(14)			(1)			(14)			3
Tax impact on adjusting items			(24)			(42)			(75)			(126)
Adjusted income from continuing operations attributable to shareholders ¹			395			343			1,098			926
Earnings per common share:
Income from continuing operations attributable to shareholders ¹ per common share (in EUR) - diluted			0.03			0.19			0.58			0.53
Adjusted income from continuing operations attributable to shareholders ¹ per common share (in EUR) - diluted			0.40			0.36			1.12			0.96

1Shareholders refers to shareholders of Koninklijke Philips N.V.

Amounts may not add up due to rounding.

Quarterly Report 2026 - Q3 13

Reconciliation of Net income to Adjusted EBITA and Adjusted EBITDA in millions of EUR

			Philips Group			Diagnosis & Treatment			Connected Care			Personal Health			Other
Q3 2026
Net income			28
Discontinued operations, net of income taxes			2
Income tax expense (benefit)			92
Results of associates			1
Financial expenses			84
Financial income			(42)
Income from operations			165			219			(195)			165			(24)
Amortization and impairment of acquired intangible assets			52			19			25			3			4
EBITA			216			239			(170)			169			(21)
Restructuring and acquisition-related charges			18			11			5			-			3
Other items:			335			5			322			-			7
Respironics DOJ settlement provision			288			-			288			-			-
Respironics consent decree charges			31			-			31			-			-
Respironics field-action running costs			3			-			3			-			-
Quality actions			6			5			-			-			-
Remaining items			7			-			-			-			7
Adjusted EBITA			569			255			157			168			(12)
Depreciation, amortization and impairment of fixed assets and other intangible assets			203			46			55			26			76
Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items			-			-			-			-			-
Adjusted EBITDA			772			301			212			195			64
January to September 2026
Net income			560
Discontinued operations, net of income taxes			2
Income tax expense (benefit)			296
Results of associates			6
Financial expenses			257
Financial income			(106)
Income from operations			1,015			665			(96)			493			(46)
Amortization and impairment of acquired intangible assets			189			58			110			10			11
EBITA			1,204			723			14			503			(35)
Restructuring and acquisition-related charges			(45)			(12)			(72)			4			36
Other items:			479			15			458			-			7
Respironics DOJ settlement provision			288			-			288			-			-
Respironics consent decree charges			80			-			80			-			-
Portfolio realignment charges			50			-			50			-			-
Respironics field-action running costs			39			-			39			-			-
Quality actions			16			15			2			-			-
Remaining items			7			-			-			-			7
Adjusted EBITA			1,638			726			399			507			7
Depreciation, amortization and impairment of fixed assets and other intangible assets			712			139			262			68			243
Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items			(101)			-			(101)			-			-
Adjusted EBITDA			2,250			864			560			575			250

Amounts may not add up due to rounding.

Quarterly Report 2026 - Q3 14

			Philips Group			Diagnosis & Treatment			Connected Care			Personal Health			Other
Q3 2025
Net income			187
Discontinued operations, net of income taxes			1
Income tax expense (benefit)			87
Results of associates			(2)
Financial expenses			78
Financial income			(21)
Income from operations			330			200			12			143			(25)
Amortization and impairment of acquired intangible assets			79			18			55			3			3
EBITA			409			217			67			147			(22)
Restructuring and acquisition-related charges			57			6			33			4			13
Other items:			65			22			36			-			7
Respironics consent decree charges			20			-			20			-			-
Respironics field-action running costs			20			-			20			-			-
Quality actions			23			22			1			-			-
Remaining items			2			-			(5)			-			7
Adjusted EBITA			531			246			137			151			(3)
Depreciation, amortization and impairment of fixed assets and other intangible assets			224			45			80			22			77
Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items			(17)			-			(15)			(1)			-
Adjusted EBITDA			738			291			201			172			74
January to September 2025
Net income			499
Discontinued operations, net of income taxes			8
Income tax expense (benefit)			208
Results of associates			6
Financial expenses			238
Financial income			(75)
Income from operations			884			579			(3)			381			(73)
Amortization and impairment of acquired intangible assets			189			56			114			11			9
EBITA			1,074			635			111			392			(65)
Restructuring and acquisition-related charges			169			36			66			13			55
Other items:			182			43			132			-			7
Respironics consent decree charges			68			-			68			-			-
Respironics field-action running costs			91			-			91			-			-
Quality actions			42			43			(2)			-			-
Contract settlement gain			(23)			-			(23)			-			-
Remaining items			4			-			(2)			-			7
Adjusted EBITA			1,425			714			309			405			(3)
Depreciation, amortization and impairment of fixed assets and other intangible assets			656			138			204			76			239
Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items			(26)			(1)			(16)			(9)			-
Adjusted EBITDA			2,056			852			497			472			235

Amounts may not add up due to rounding.

Quarterly Report 2026 - Q3 15

Composition of free cash flow in millions of EUR

			Q3						January to September
			2026			2025			2026			2025
Net cash flows from operating activities			544			327			1,108			(219)
Net capital expenditures			(160)			(155)			(473)			(469)
Purchase of intangible assets			(26)			(23)			(80)			(92)
Expenditures on development assets			(61)			(67)			(189)			(198)
Capital expenditures on property, plant and equipment			(75)			(68)			(212)			(186)
Proceeds from sales of property, plant and equipment			2			3			9			7
Free cash flow			384			172			635			(688)

Composition of net debt to group equity in millions of EUR unless otherwise stated

			September 30, 2026			December 31, 2025
Long-term debt			6,985			6,934
Short-term debt			1,154			1,151
Total debt			8,139			8,084
Cash and cash equivalents			2,751			2,794
Net debt			5,387			5,290
Shareholders’ equity			11,580			10,957
Non-controlling interests			29			32
Group equity			11,609			10,990
Net debt : group equity ratio			32:68			32:68

Amounts may not add up due to rounding.

Quarterly Report 2026 - Q3 16

Philips statistics

Quarterly statistics in millions of EUR unless otherwise stated

			2026												2025
			Q1			Q2			Q3			Q4			Q1			Q2			Q3			Q4
Sales			3,905			4,360			4,393						4,097			4,338			4,302			5,097
Nominal sales growth			(5		%)	1		%	2		%				(1		%)	(3		%)	(2		%)	1		%
Comparable sales growth ¹			4		%	4		%	3		%				(2		%)	1		%	3		%	7		%
Comparable order intake ²			6		%	(1		%)	8		%				2		%	6		%	8		%	7		%
Gross margin			1,766			2,150			2,040						1,849			2,011			1,911			2,288
as a % of sales			45		%	49		%	46		%				45		%	46		%	44		%	45		%
Selling expenses			(1,007)			(1,053)			(1,016)						(1,087)			(1,084)			(1,024)			(1,147)
as a % of sales			(26		%)	(24		%)	(23		%)				(27		%)	(25		%)	(24		%)	(23		%)
G&A expenses			(177)			(154)			(158)						(161)			(155)			(154)			(158)
as a % of sales			(5		%)	(4		%)	(4		%)				(4		%)	(4		%)	(4		%)	(3		%)
R&D expenses			(394)			(484)			(410)						(457)			(402)			(414)			(427)
as a % of sales			(10		%)	(11		%)	(9		%)				(11		%)	(9		%)	(10		%)	(8		%)
Income from operations			241			609			165						154			400			330			540
as a % of sales			6		%	14		%	4		%				4		%	9		%	8		%	11		%
Net income			146			386			28						72			240			187			397
Income from continuing operations attributable to shareholders ³ per common share (in EUR) - diluted			0.16			0.40			0.03						0.09			0.25			0.19			0.41
Adjusted income from continuing operations attributable to shareholders ³ per common share (in EUR) - diluted ¹			0.23			0.49			0.40						0.25			0.36			0.36			0.60
EBITA ¹			292			697			216						211			453			409			591
as a % of sales			7.5		%	16.0		%	4.9		%				5.2		%	10.5		%	9.5		%	11.6		%
Adjusted EBITA ¹			353			717			569						354			540			531			770
as a % of sales			9.0		%	16.4		%	13.0		%				8.6		%	12.4		%	12.3		%	15.1		%
Adjusted EBITDA ¹			567			910			772						571			747			738			991
as a % of sales			14.5		%	20.9		%	17.6		%				13.9		%	17.2		%	17.2		%	19.4		%
At the end of period:
Number of common shares outstanding (after deduction of treasury shares) in thousands			952,018			977,427			977,614						925,084			950,574			950,979			951,289
Shareholders’ equity per common share in EUR			11.97			11.71			11.85						12.64			10.92			11.10			11.52
Net debt : group equity ratio ¹			33:67			33:67			32:68						35:65			39:61			38:62			32:68
Philips employees			64,317			63,670			63,909						65,553			65,566			65,284			64,817

1Non-IFRS financial measure. Refer to the Reconciliation of non-IFRS information

2Comparable order intake is presented when discussing the Philips Group's performance. For the definition of this measure, refer to chapter Further information, section Other Key Performance Indicators, of the Annual Report 2025.

3Shareholders refers to shareholders of Koninklijke Philips N.V.

Quarterly Report 2026 - Q3 17

Year-to-date statistics in millions of EUR unless otherwise stated

			2026												2025
			January-March			January-June			January-September			January-December			January-March			January-June			January-September			January-December
Sales			3,905			8,265			12,658						4,097			8,434			12,736			17,834
Nominal sales growth			(5		%)	(2		%)	(1		%)				(1		%)	(2		%)	(2		%)	(1		%)
Comparable sales growth ¹			4		%	4		%	3		%				(2		%)	(1		%)	1		%	2		%
Comparable order intake ²			6		%	2		%	4		%				2		%	4		%	6		%	6		%
Gross margin			1,766			3,916			5,956						1,849			3,859			5,770			8,058
as a % of sales			45		%	47		%	47		%				45		%	46		%	45		%	45		%
Selling expenses			(1,007)			(2,060)			(3,077)						(1,087)			(2,171)			(3,195)			(4,342)
as a % of sales			(26		%)	(25		%)	(24)		%				(27		%)	(26		%)	(25		%)	(24		%)
G&A expenses			(177)			(332)			(490)						(161)			(316)			(470)			(628)
as a % of sales			(5		%)	(4		%)	(4)		%				(4		%)	(4		%)	(4		%)	(4		%)
R&D expenses			(394)			(878)			(1,288)						(457)			(859)			(1,273)			(1,700)
as a % of sales			(10		%)	(11)		%	(10)		%				(11		%)	(10		%)	(10		%)	(10		%)
Income from operations			241			851			1,015						154			554			884			1,424
as a % of sales			6		%	10		%	8		%				4		%	7		%	7		%	8		%
Net income			146			532			560						72			312			499			897
Income from continuing operations attributable to shareholders ³ per common share (in EUR) - diluted			0.16			0.55			0.58						0.09			0.34			0.53			0.93
Adjusted income from continuing operations attributable to shareholders ³ per common share (in EUR) - diluted ¹			0.23			0.73			1.12						0.25			0.61			0.96			1.56
EBITA ¹			292			988			1,204						211			665			1,074			1,665
as a % of sales			7.5		%	12.0		%	9.5		%				5.2		%	7.9		%	8.4		%	9.3		%
Adjusted EBITA ¹			353			1,069			1,638						354			894			1,425			2,195
as a % of sales			9.0		%	12.9		%	12.9		%				8.6		%	10.6		%	11.2		%	12.3		%
Adjusted EBITDA ¹			567			1,478			2,250						571			1,317			2,056			3,046
as a % of sales			14.5		%	17.9		%	17.8		%				13.9		%	15.6		%	16.1		%	17.1		%

1Non-IFRS financial measure. Refer to the Reconciliation of non-IFRS information

2Comparable order intake is presented when discussing the Philips Group's performance. For the definition of this measure, refer to chapter Further information, section Other Key Performance Indicators, of the Annual Report 2025.

3Shareholders refers to shareholders of Koninklijke Philips N.V.

© 2026 Koninklijke Philips N.V. All rights reserved.
https://www.philips.com/investorrelations